In 3 pivotal trials, adult patients with moderate-to-severe atopic dermatitis not adequately controlled with topical treatments were randomized to DUPIXENT 300 mg Q2W or placebo. In Trial 3, concomitant TCS was used. The primary endpoint was the change from baseline to Week 16 in the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and ≥2-point improvement. The IGA, performed by a healthcare professional, is a visual evaluation of the overall assessment of atopic dermatitis lesions on a severity scale of 0 (clear) to 4 (severe).1,2
For all patients, moderate-to-severe atopic dermatitis was treated with concomitant TCS. Results are presented at 16 and 52 weeks.1,d
TCS, topical corticosteroids.